Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

Completion of the first adult dose cohort, which received the lowest dose of HG-CT-1, represents a pivotal milestone in the Company's trial. If no dose-limiting toxicities are observed, Hemogenyx ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

NEW YORK, NY, USA I August 14, 2025 I Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, ...

Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development ...

Investing.com -- Schrodinger Inc (NASDAQ:SDGR) stock plunged 13.7% after the company announced it is discontinuing the clinical development program for its CDC7 inhibitor SGR-2921, which was being ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

Schrodinger (SDGR) announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated ...

GAAP EPS was $(0.49) for Q2 2025, missing analyst estimates by 22.3%. Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 ...